XML 61 R47.htm IDEA: XBRL DOCUMENT v3.21.2
License Agreements - Novartis (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 143 Months Ended
Jun. 30, 2020
May 31, 2020
Apr. 30, 2016
Sep. 30, 2014
Jan. 31, 2010
Dec. 31, 2009
Nov. 30, 2009
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Dec. 31, 2020
License agreements                          
Revenues               $ 812,987 $ 620,643 $ 2,123,414 $ 1,877,193    
JAKAFI                          
License agreements                          
Revenues               547,373 487,783 1,542,138 1,420,968    
Novartis                          
License agreements                          
Upfront and immediate milestone payment to be received under license agreement             $ 210,000            
Upfront payment received under license agreement           $ 150,000              
Immediate milestone payment received under license agreement         $ 60,000                
Revenues                 0   90,000    
Royalties payable               132,400   132,400   $ 132,400 $ 96,400
Reimbursable costs included in accounts receivable               200   200   200 $ 200
Research and development expenses reimbursed               0 0 100 300    
Novartis | Pre-specified Events | Maximum                          
License agreements                          
Upfront and immediate milestone payment to be received under license agreement             1,200,000            
Novartis | Development Milestones                          
License agreements                          
Amount recognized and received for the achievement of a predefined milestone                       157,000  
Novartis | Development Milestones | Maximum                          
License agreements                          
Upfront and immediate milestone payment to be received under license agreement             174,000            
Novartis | Regulatory Milestones                          
License agreements                          
Amount recognized and received for the achievement of a predefined milestone                       280,000  
Novartis | Regulatory Milestones | Maximum                          
License agreements                          
Upfront and immediate milestone payment to be received under license agreement             495,000            
Novartis | Sales and Commercial Milestones                          
License agreements                          
Amount recognized and received for the achievement of a predefined milestone                       $ 200,000  
Novartis | Sales and Commercial Milestones | Maximum                          
License agreements                          
Upfront and immediate milestone payment to be received under license agreement             $ 500,000            
Novartis | TABRECTA                          
License agreements                          
Revenues               2,700 1,400 7,300 2,100    
Novartis | TABRECTA | Development Milestones                          
License agreements                          
Amount recognized and received for the achievement of a predefined milestone   $ 25,000                      
Novartis | TABRECTA | Regulatory Milestones                          
License agreements                          
Amount recognized and received for the achievement of a predefined milestone   $ 45,000                      
Novartis | TABRECTA | Regulatory Milestones | JAPAN                          
License agreements                          
Amount recognized and received for the achievement of a predefined milestone $ 20,000                        
Novartis | GVHD | Development and Regulatory Milestones | Maximum                          
License agreements                          
Upfront and immediate milestone payment to be received under license agreement     $ 75,000                    
Novartis | JAKAFI | U.S.                          
License agreements                          
Royalties payable on net sales               26,900 23,900 70,600 64,600    
Novartis | JAKAVI                          
License agreements                          
Revenues               $ 94,700 $ 68,300 $ 242,300 $ 190,900    
Novartis | JAKAVI | Minimum                          
License agreements                          
Royalty payments on future global net sales (as a percent)                   12.00%      
Novartis | JAKAVI | Maximum                          
License agreements                          
Royalty payments on future global net sales (as a percent)                   14.00%      
Novartis | JAKAVI | Regulatory Milestones | Europe                          
License agreements                          
Amount recognized and received for the achievement of a predefined milestone       $ 60,000